Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Didronel PMO

M Stone1

  • 1Cardiff Royal Infirmary.

British Journal of Hospital Medicine
|February 2, 1993
PubMed
Summary
This summary is machine-generated.

New treatment Didronel PMO, a combination of disodium etidronate and calcium carbonate, significantly reduces vertebral fracture rates by 50% in postmenopausal women with existing fractures after two years.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First national study on genomic profiling of <i>Escherichia coli</i> in United Arab Emirates (UAE) aquatic environments shows diverse Quinolone and Cephalosporin resistance.

Environmental challenges (Amsterdam, Netherlands)·2025
Same author

Estimated US Trends in SARS-CoV-2 Spike Antibody Concentrations and Correlation to Risk of First-Time Infections Based on Blood Donations, 2022.

The Journal of infectious diseases·2025
Same author

Advancing mechanistic understanding of cohesive sediment transport: Integrating flume experiments, field measurements, and modelling approaches in a gravel-bed river.

The Science of the total environment·2024
Same author

Veterinary Services'use of the Global Burden of Animal Diseases to prioritise interventions, monitor impact and develop critical competencies.

Revue scientifique et technique (International Office of Epizootics)·2024
Same author

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

The effect of shear-dependent flocculation on the multimodality of effective particle size distributions in a gravel-bed river during high flows.

Journal of soils and sediments·2023
Same journal

The autopsy in the 1990s.

British journal of hospital medicine·1999
Same journal

Screening for breast cancer.

British journal of hospital medicine·1999
Same journal

Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension.

British journal of hospital medicine·1999
Same journal

Liposarcoma: a review of current diagnosis and management.

British journal of hospital medicine·1999
Same journal

How to do it in surgery: laparoscopic rectopexy.

British journal of hospital medicine·1999
Same journal

The management of ovarian cancer.

British journal of hospital medicine·1999
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Postmenopausal osteoporosis is a significant health concern, increasing fracture risk.
  • Vertebral fractures are common complications of osteoporosis, leading to morbidity.
  • Existing treatments aim to reduce bone loss and fracture incidence.

Purpose of the Study:

  • To evaluate the efficacy of Didronel PMO in reducing vertebral fracture rates.
  • To assess the safety and tolerability of the new treatment regimen.

Main Methods:

  • A clinical trial involving women with postmenopausal osteoporosis and at least one vertebral fracture.
  • Treatment involved cyclical administration of disodium etidronate and calcium carbonate.
  • Vertebral fracture incidence was monitored over a 2-year period.

Related Experiment Videos

Main Results:

  • Didronel PMO treatment resulted in a 50% reduction in vertebral fracture rates.
  • The treatment demonstrated significant efficacy in preventing new fractures.
  • No major adverse events were reported, indicating a favorable safety profile.

Conclusions:

  • Didronel PMO is an effective new treatment for postmenopausal osteoporosis in women with existing vertebral fractures.
  • The combination therapy offers a promising approach to reduce fracture burden in this high-risk population.